Novo’s Wegovy Pill Wins Approval in UK for Obesity Treatment

Novo Nordisk A/S has received approval in the UK for its Wegovy pill, designed for obesity treatment. This development targets individuals who prefer oral medication over injectable shots, expanding the company's reach within the obesity market. Following the announcement of this regulatory win, Novo Nordisk stock experienced a rise. The approval intensifies the competitive race to launch effective weight-loss pills, positioning the company to capture a broader patient demographic through this new delivery method.